Technology Applications: Use of Digital Health Technology to Enable Drug Development.

Autor:	Liu JF; Joyce F. Liu, Dana Farber Cancer Institute, Boston; Ellie Strock, Ruth Phillips, and Karine Mari, Voluntis, Cambridge, MA; Jung-min Lee, Elise C. Kohn, and S. Percy Ivy, National Cancer Institute, Bethesda, MD; Bill Killiam, User-Centered Design, Ashburn, VA; and Matthew Bonam and Tsveta Milenkova, AstraZeneca, Cambridge, United Kingdom., Lee JM; Joyce F. Liu, Dana Farber Cancer Institute, Boston; Ellie Strock, Ruth Phillips, and Karine Mari, Voluntis, Cambridge, MA; Jung-min Lee, Elise C. Kohn, and S. Percy Ivy, National Cancer Institute, Bethesda, MD; Bill Killiam, User-Centered Design, Ashburn, VA; and Matthew Bonam and Tsveta Milenkova, AstraZeneca, Cambridge, United Kingdom., Strock E; Joyce F. Liu, Dana Farber Cancer Institute, Boston; Ellie Strock, Ruth Phillips, and Karine Mari, Voluntis, Cambridge, MA; Jung-min Lee, Elise C. Kohn, and S. Percy Ivy, National Cancer Institute, Bethesda, MD; Bill Killiam, User-Centered Design, Ashburn, VA; and Matthew Bonam and Tsveta Milenkova, AstraZeneca, Cambridge, United Kingdom., Phillips R; Joyce F. Liu, Dana Farber Cancer Institute, Boston; Ellie Strock, Ruth Phillips, and Karine Mari, Voluntis, Cambridge, MA; Jung-min Lee, Elise C. Kohn, and S. Percy Ivy, National Cancer Institute, Bethesda, MD; Bill Killiam, User-Centered Design, Ashburn, VA; and Matthew Bonam and Tsveta Milenkova, AstraZeneca, Cambridge, United Kingdom., Mari K; Joyce F. Liu, Dana Farber Cancer Institute, Boston; Ellie Strock, Ruth Phillips, and Karine Mari, Voluntis, Cambridge, MA; Jung-min Lee, Elise C. Kohn, and S. Percy Ivy, National Cancer Institute, Bethesda, MD; Bill Killiam, User-Centered Design, Ashburn, VA; and Matthew Bonam and Tsveta Milenkova, AstraZeneca, Cambridge, United Kingdom., Killiam B; Joyce F. Liu, Dana Farber Cancer Institute, Boston; Ellie Strock, Ruth Phillips, and Karine Mari, Voluntis, Cambridge, MA; Jung-min Lee, Elise C. Kohn, and S. Percy Ivy, National Cancer Institute, Bethesda, MD; Bill Killiam, User-Centered Design, Ashburn, VA; and Matthew Bonam and Tsveta Milenkova, AstraZeneca, Cambridge, United Kingdom., Bonam M; Joyce F. Liu, Dana Farber Cancer Institute, Boston; Ellie Strock, Ruth Phillips, and Karine Mari, Voluntis, Cambridge, MA; Jung-min Lee, Elise C. Kohn, and S. Percy Ivy, National Cancer Institute, Bethesda, MD; Bill Killiam, User-Centered Design, Ashburn, VA; and Matthew Bonam and Tsveta Milenkova, AstraZeneca, Cambridge, United Kingdom., Milenkova T; Joyce F. Liu, Dana Farber Cancer Institute, Boston; Ellie Strock, Ruth Phillips, and Karine Mari, Voluntis, Cambridge, MA; Jung-min Lee, Elise C. Kohn, and S. Percy Ivy, National Cancer Institute, Bethesda, MD; Bill Killiam, User-Centered Design, Ashburn, VA; and Matthew Bonam and Tsveta Milenkova, AstraZeneca, Cambridge, United Kingdom., Kohn EC; Joyce F. Liu, Dana Farber Cancer Institute, Boston; Ellie Strock, Ruth Phillips, and Karine Mari, Voluntis, Cambridge, MA; Jung-min Lee, Elise C. Kohn, and S. Percy Ivy, National Cancer Institute, Bethesda, MD; Bill Killiam, User-Centered Design, Ashburn, VA; and Matthew Bonam and Tsveta Milenkova, AstraZeneca, Cambridge, United Kingdom., Ivy SP; Joyce F. Liu, Dana Farber Cancer Institute, Boston; Ellie Strock, Ruth Phillips, and Karine Mari, Voluntis, Cambridge, MA; Jung-min Lee, Elise C. Kohn, and S. Percy Ivy, National Cancer Institute, Bethesda, MD; Bill Killiam, User-Centered Design, Ashburn, VA; and Matthew Bonam and Tsveta Milenkova, AstraZeneca, Cambridge, United Kingdom.
Jazyk:	angličtina
Zdroj:	JCO clinical cancer informatics [JCO Clin Cancer Inform] 2018 Dec; Vol. 2, pp. 1-12.
DOI:	10.1200/CCI.17.00153
Abstrakt:	Purpose: This pilot study developed and evaluated the feasibility, usability, and perceived satisfaction with an end-user mobile medical application and provider web portal. The two interfaces allowed for remote monitoring, provided daily guidance in the management of hypertension and diarrhea, and allowed for rapid management of adverse events during a clinical trial of olaparib and cediranib. Patients and Methods: eCO (eCediranib/Olaparib) was designed for patient self-reported, real-time management of hypertension and diarrhea using remote monitoring. eCO links to a Bluetooth-enabled blood pressure (BP) monitor and transmits data to a secure provider web portal. eCO use was assessed for suitability, usability, and satisfaction after 4 weeks using a 17-item questionnaire. Metrics regarding patient-reported BP and diarrhea events were analyzed. Results: Sixteen patients enrolled in the pilot. A total of 98.2% of expected BP values were reported: 94.2% via Bluetooth and 5.8% entered manually. Twelve patients experienced 21 BP events (systolic BP > 140 and/or diastolic BP > 90 mmHg on two consecutive readings); data from cycle 1 were comparable to the study database. Thirteen patients reported diarrhea (more than one stool per 24 hours over baseline) categorized as grade 1 or 2, which was comparable to the study database. Survey analysis showed that patients had statistically significant, positive responses to the use of the eCO application. Patients indicated eCO use made them feel more involved in their care and better connected to their health care team. The only aspect of the application that did not show a statistically significant positive response was the process of reporting diarrhea. Conclusion: The eCO application was designed to assist in managing acute treatment-related events most often associated with treatment discontinuation, need for drug holidays, or dose interruption. Hypertension and diarrhea events reported via eCO allowed rapid provider response and a positive overall patient experience.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu